AVM Biotechnology is a Seattle-based company specializing in the development and advancement of AVM0703, a proprietary formulation of concentrated dexamethasone. This unique formulation allows for high dosing, activating the release and production of the body's supercharged gamma delta Natural Killer T-like AVM-NKT immune cells, which have distinct immune response properties. With broad applications in cancer treatment and autoimmune syndromes, AVM Biotechnology aims to unlock the untapped potential of the human immune system to save lives and improve outcomes.
Committed to unleashing the human immune potential, AVM Biotechnology is dedicated to developing and delivering innovative treatments that harness the body's own immune system. Through their research and clinical trials, they have demonstrated the significant role that AVM-NKT cells can play in various diseases and conditions. By focusing on the power of the immune system, AVM Biotechnology strives to provide advanced solutions to complex diseases, ultimately aiming to improve the lives of patients worldwide.
Generated from the website